Kit for detecting the HLA-C*06 alleles by Real Time PCR using TaqMan® probes technology

Information about the product

Psoriasis vulgaris is a chronic inflammatory disease of skin, which affects 2% of world population. The cutaneous manifestations of psoriasis are obvious and have a negative impact on quality of life of patients.

Family studies have demonstrated that psoriasis has a genetic and multifactorial basis in most of cases. In fact, there is a clear association between psoriasis and HLA genes. More specifically, HLA-C*06 group of alleles has been identified as the main psoriasis marker which gives more susceptibility to suffer this disease.

In addition, several studies have demonstrated a significant increasing response to Ustekinumab treatment in HLA-C*06 positive patients: HLA-C*06 positive patients respond faster and to a greater extent to Ustekinumab than HLA-C*06 negative ones.

All of the above highlights the role of HLA-C*06 not only as a psoriasis susceptibility marker, but also as a pharmacogenetic marker of Ustekinumab response in psoriasis.

Intended use

Genvinset® HLA C*06 is a semi-automated in vitro diagnostic kit for HLA-C*06 group of alleles qualitative detection in genomic DNA extracted from whole blood, associated with psoriasis susceptibility and its treatment effectiveness, by real-time PCR using TaqMan® probes technology.

Patients who can benefit from this determination are those referred by a specialist. The results of this test should not be the only ones on which the therapeutic decision is based and should be used as an aid in the diagnosis together with results of other markers of the disease.

The intended user of the kit is technical personnel trained to carry out the protocol and the interpretation of results described in the instructions for use.

Workflow

workflow genvinset 2
Genvinset® HLA C*06 5

Results

Genvinset HLA C06 Negative sample
Genvinset HLA C06 Positive sample
leyenda 5
Genvinset® HLA C*06 6

Limitations

  • Mutations or polymorphisms at annealing primer/probe sites are possible and may result in the lack of allele definition. Other technologies could be necessary to resolve the typing.
  • Data and result interpretation should be revised by qualified personnel.
  • This product is an auxiliary tool for the diagnosis of patients with suspected psoriasis and can help assess the administration of the correct treatment. Use these results in conjunction with clinical data and results of other tests performed on the patient.

Area:

HLA associated diseases, HLA associated diseases, Immunology, Molecular Genetics, Targeted study of specific pathologies

Documents:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

SOPHiA DDM GEN2

Analytical platform for clinical genomics that enables the detection, annotation, and interpretation of genomic variants using artificial intelligence to support patient diagnosis and treatment. Detailed Description SOPHiA DDM™ Platform is an advanced solution for precision medicine workflows, with a renewed interface, web access, and new functionalities to accelerate genomic data analysis. It offers end‑to‑end workflows…
SOPHIA Genetics

PGT-SR (Preimplantation Genetic Testing for Chromosomal Structural Rearrangements)

PGT‑SR (Preimplantation Genetic Testing for Structural Chromosomal Rearrangements) is a solution aimed at the analysis of structural chromosomal rearrangements in embryos. According to the product literature, it is based on single‑cell whole‑genome amplification and NGS sequencing to detect embryos from patients with chromosomal abnormalities and select euploid embryos for transfer, with the aim of reducing…
Yikon Genomics
Next Generation Sequencing (NGS)

MaReCs (Mapping allele with resolved carrier state test)

MaReCs® (Allelic Mapping with Resolved Carrier Status) is a PGT‑SR technology that first identifies aneuploid or euploid embryos and then analyses translocation breakpoints and SNP linkage to differentiate carrier from non‑carrier euploid embryos. Detailed Description Principle of operation MaReCs® combines ChromSwift® technology with NGS sequencing to perform a CNV analysis and subsequently an SNP linkage…
Yikon Genomics
Next Generation Sequencing (NGS)

KaryoSeq (Integrated solution for PGT-M, PGT-SR and PGT-A)

KaryoSeq™ is a next‑generation sequencing (NGS)‑based solution for preimplantation genetic testing that enables PGT‑M, PGT‑SR and PGT‑A within a single workflow. It is designed for the analysis of DNA extracted from 3 to 10 trophectoderm cells of human embryos at the blastocyst stage. Detailed Description Principle of operation KaryoSeq™ is based on the MARSALA principle…
Yikon Genomics
Next Generation Sequencing (NGS)